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Abstract
Inflammation and oxidative stress play a crucial role in angiotensin (Ang) II-mediated vascular injury. Angiotensin-converting
enzyme 2 (ACE2) has recently been identified as a specific Ang II-degrading enzyme but its role in vascular biology remains
elusive. We hypothesized that loss of ACE2 would facilitate Ang II-mediated vascular inflammation and peroxynitrite
production. 10-week wildtype (WT, Ace2
+/y) and ACE2 knockout (ACE2KO, Ace2
2/y) mice received with mini-osmotic pumps
with Ang II (1.5 mg.kg
21.d
21) or saline for 2 weeks. Aortic ACE2 protein was obviously reduced in WT mice in response to
Ang II related to increases in profilin-1 protein and plasma levels of Ang II and Ang-(1–7). Loss of ACE2 resulted in greater
increases in Ang II-induced mRNA expressions of inflammatory cytokines monocyte chemoattractant protein-1 (MCP-1),
interleukin (IL)-1b, and IL-6 without affecting tumor necrosis factor-a in aortas of ACE2KO mice. Furthermore, ACE2
deficiency led to greater increases in Ang II-mediated profilin-1 expression, NADPH oxidase activity, and superoxide and
peroxynitrite production in the aortas of ACE2KO mice associated with enhanced phosphorylated levels of Akt, p70S6
kinase, extracellular signal-regulated kinases (ERK1/2) and endothelial nitric oxide synthase (eNOS). Interestingly, daily
treatment with AT1 receptor blocker irbesartan (50 mg/kg) significantly prevented Ang II-mediated aortic profilin-1
expression, inflammation, and peroxynitrite production in WT mice with enhanced ACE2 levels and the suppression of the
Akt-ERK-eNOS signaling pathways. Our findings reveal that ACE2 deficiency worsens Ang II-mediated aortic inflammation
and peroxynitrite production associated with the augmentation of profilin-1 expression and the activation of the Akt-ERK-
eNOS signaling, suggesting potential therapeutic approaches by enhancing ACE2 action for patients with vascular diseases.
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Introduction
Vascular inflammation and oxidative stress play a crucial role in
the pathogenesis of vascular injury mediated by angiotensin (Ang)
II, the major effector peptide of the renin-angiotensin system
(RAS) [1–3]. Ang II has recently been shown to induce vascular
injury by modulating release of inflammatory chemokines such as
monocyte chemoattractant protein-1 (MCP-1), interleukin (IL)-1b,
IL-6 [2,3] and promoting the NADPH oxidase activation and
superoxide (O2
–) production [4,5], contributing to endothelial
nitric oxide (NO) synthase (eNOS) uncoupling and impaired NO
bioavailability as well as vascular oxidative stress [1,6,7]. Within
the vascular system, Ang II-mediated superoxide may drive a very
fast radical-radical reaction by reacting with NO to yield the much
more powerful oxidant peroxynitrite (ONOO
2), which causes
profound vascular injury via oxidative and nitrosative reactions
[8]. In addition, Ang II is a well-known activator of profilin-1,
extracellular signal-regulated kinases (ERK) and phosphatidylino-
sitol 3-kinase (PI3K)/Akt signaling cascades, leading to increased
formation of nitrotyrosine, an index of peroxynitrite damage to
vascular tissues [1,9,10,11,12]. The actin-binding protein profilin-
1 has been shown to directly activate Akt/ERK signaling
pathways, which are important contributors of eNOS uncoupling
and peroxynitrite generation in the vasculature [11,13,14].
However, little is known regarding the relationship among
profilin-1, inflammation and peroxynitrite production in the
vascular diseases.
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e38502Pharmacological inhibition of the Ang II signaling is a key
aspect of the current approach to preventing vascular inflamma-
tion and oxidative stress-related vascular dysfunction [15].
Rencently, angiotensin-converting enzyme 2 (ACE2) has been
identified as a pleiotropic monocarboxypeptidase responsible for
the degradation of Ang II to the vasodilatory Ang-(1–7), which has
been shown to counteract the pro-inflammatory and pro-oxidative
effects of Ang II via its receptor Mas, thereby functioning as
a negative regulator of the RAS [5,16,17,18]. Intriguingly, the Ang
II type 1 (AT1) receptor blockers may increase expression and
activity of ACE2 [9,19] with attenuation of cardiovascular
oxidative damage [20] and diminish the profilin-1/ERK signaling
[9,10,21]. In our previously studies, we demonstrated that ACE2
deficiency mice develop impaired cardiac functions, pathological
remodeling with enhanced inflammatory cytokines, oxidative
stress and ERK1/2 activation in heart [20,22,23] whereas
ACE2 overexpression prevents Ang II-induced inflammation,
oxidative stress and ERK1/2 activation in association with an
attenuation of cardiovascular remodeling and dysfunction
[9,23,24], suggesting a critical role ACE2 in regulation of
inflammation, oxidative stress and cardiovascular function. How-
ever, the exact role and mechanism of ACE2 in vascular biology
remain largely unknown. In this work, we assessed the hypothesis
that loss of ACE2 would facilitate vascular inflammation and
peroxynitrite production. We randomized ACE2 knockout
(ACE2KO, Ace2
2/y) and wild-type littermates (WT, Ace2
+/y)
mice to either Ang II or saline infusion as in the previous study
[23,24]. To investigate whether Ang II-induced pathological
effects in the aortas of mice are mediated by AT1 receptor, we
used irbesartan as a specific blocker of AT1 receptor.
Materials and Methods
Experimental Animals and Protocols
Mutant mice have been previously described [20,22,25]. 10-
week male WT and ACE2KO mice received with mini-osmotic
pumps (model 1002, Alza Corp, Palo Alto, CA) with Ang II
(1.5 mg.kg
21.d
21) or saline for 2 weeks [24]. WT mice were
treated with irbesartan (50 mg.kg
21.d
21; Bristol-Myers Squibb
Co., Princeton, NJ) in their drinking water for 3 days before Ang
II infusion and during the course of the study. Plasma levels of Ang
II and Ang-(1–7) were measured by radio-immunoassay in the
Hypertension and Vascular Disease Centre Core Laboratory at
Wake Forest University School of Medicine as previously de-
scribed [20,25]. The thoracic aorta was carefully isolated from the
mice anesthetized with a mixture (100 mg/kg ketamine plus
10 mg/kg xylaxine; ip) at the end of the experiment. All
experiments were approved and performed in accordance with
the Guide for the Care and Use of Laboratory Animals published by the US
National Institutes of Health (NIH Publication No. 85-23, revised
1996), the Canadian Council on Animal Care and the Animal
Research Ethics Committee at Shanghai Jiao Tong University
School of Medicine.
Dihydroethidium and Nitrotyrosine Fluorescence
Oxidative stress is generally identified by indirect markers of the
vascular oxidant damage, such as superoxide and peroxynitrite
production [6,26]. The oxidative fluorescent dye dihydroethidium
(DHE) and nitrotyrosine staining were used to evaluate superoxide
(O2
–) and peroxynitrite (ONOO
–) levels in aorta tissues as
previously described [23,24,26]. For aortic DHE staining, 20 mm
fresh frozen tissue sections were washed with hanks balanced salt
solution (HBSS) with magnesium and calcium and then incubated
at 37uC for 30 min with DHE (10 mM) in HBSS. For nitrotyrosine
staining, aortic tissue sections were immunostained using poly-
clonal nitrotyrosine antibodies (1:100; Upstate Biotechnology Inc,
Lake Placid, NY). Fluorescent images were observed with an
Olympus Fluoview laser-scanning confocal microscope mounted
on an Olympus microscope.
Measurement of NADPH Oxidase Activity
The NADPH oxidase activities in aorta tissues of mice were
quantified by lucigenin-enhanced chemiluminescence as previous-
ly described [20]. Briefly, the aorta homogenates were collected in
100 ml of phosphate buffer solution (PBS) mixture with protease
inhibitor and phosphatase inhibitor and centrifuged at 1000 g for
10 min. The supernatants were then collected and added lucigenin
(50 mM) and NADPH (1 mM) for NADPH oxidase activities assay
with FB-12 luminometer in the absence or presence of
diphenylene iodonium (10 mM), a selective inhibitor of NADPH
oxidase. All data were calculated as the change in the rate of
luminescence per minute per milligram of aorta tissue.
TaqMan Real-time PCR Analysis
The mRNA expression levels were determined by TaqMan
real-time reverse transcription PCR as previously described
[5,23,27]. Total RNA was extracted from flash-frozen aorta
tissues using TRIzol reagent, and cDNA was synthesized from
1 mg total RNA by using random hexamers. The primers and
probes for mouse ACE2, MCP-1, IL-1b, IL-6, and tumor necrosis
factor-a (TNF-a) are indicated in Table 1 based on previously
published reports [5,23,27]. For each gene, a standard curve was
generated using known concentrations of cDNA as a function of
cycle threshold (CT). The mRNA expression of the reported genes
was performed by TaqMan Real-time PCR using ABI 7900
Sequence Detection System and analyzed using the SDS2.2
software (Applied. Biosystems). All samples were run in triplicates.
18S rRNA was used as an endogenous control.
Table 1. Primers and probes sequences for TaqMan real-time
PCR analysis*.
Genes Primers/Probes Sequences (Probe: 59-FAM- -TAMRA-39)
ACE2 Forward Primer 59-GATACCTACCCTTCCTACATCAGC-39
Reverse Primer 59-CTACCCCACATATCACCAAGCA-39
Probe 59-CCACTGGATGCCTCCCTGCCC-39
MCP-1 Forward Primer 59-CCTGGATCGGAACCAAATGA-39
Reverse Primer 59-CGGGTCAACTTCACATTCAAAG-39
Probe 59-AACTGCATCTGCCCTAAGGTCTTCAGCA-39
IL-1b Forward Primer 59-AACCTGCTGGTGTGTGACGTTC-39
Reverse Primer 59-CAGCACGAGGCTTTTTTGTTGT-39
Probe 59-TTAGACAGCTGCACTACAGGCTCCGAGATG-39
IL-6 Forward Primer 59-ACAACCACGGCCTTCCCTACTT-39
Reverse Primer 59-CACGATTTCCCAGAGAACATGTG-39
Probe 59-TTCACAGAGGATACCACTCCCAACAGACCT-39
TNFa Forward Primer 59-ACAAGGCTGCCCCGACTAC-39
Reverse Primer 59-TTTCTCCTGGTATGAGATAGCAAATC-39
Probe 59-TGCTCCTCACCCACACCGTCAGC-39
*Primer/probe mix for 18S were obtained from Applied Biosystems Inc. ACE2,
angiotensin-converting enzyme 2; MCP-1, monocyte chemoattractant protein-
1; IL1b, interleukin-1b; IL6, interleukin-6; TNFa, tumor necrosis factor-a.
doi:10.1371/journal.pone.0038502.t001
ACE2, Vascular Inflammation and Peroxynitrite
PLoS ONE | www.plosone.org 2 June 2012 | Volume 7 | Issue 6 | e38502Western Blot Analysis
Western blot analyses were measured as previously described
[12,18]. Antibodies against ACE2 (90 kD), profilin-1 (15 kD), Akt
(60 kD), ERK1/2 (44/42 kD), eNOS (140 kD), phospho-ERK1/
2 (44/42 kD), phspho-p70S6 kinase (70 kD), phospho-Akt
(Ser
473; 60 kD), phospho-Akt (Thr
308; 60 kD), phospho-eNOS
(Ser
1177;140 kD), nitrotyrosine (60 kD) and a-tubulin (55 kD)
were obtained from R&D Systems (Minneapolis, MN), Santa
Cruz Biotechnology (Santa Cruz, CA), and Cell Signaling
Technology (Beverly, MA), respectively. Protein samples from
thoracic aorta tissues were separated by 8%,15% SDS-poly-
acrylamide gel electrophoresis and then transferred to PVDF
membrane (Millipore). The membrane was blocked with 5%
milk in Tris-Buffered Saline Tween-20 (TBST) for 2 h and then
incubated overnight at 4uC with primary antibody. The
membrane was washed thoroughly with TBST and then
incubated with goat anti-rabbit IgG coupled to horseradish
peroxidase (HRP) in TBST for l h at room temperature, then
rinsed thoroughly with TBST as before. Aim proteins were
detected by ECL using X-O-Mat X-ray film and analyzed by the
ImageJ software (U.S. National Institutes of Health, Bethesda,
MD).
Statistical Analysis
All data are shown as mean6SEM. All statistical analyses were
performed with SPSS 11.5 software either by Student’s t test or
by ANOVA followed by the Student-Neuman-Keuls test for
multiple-comparison testing as appropriate. A value of P,0.05
was considered statistically significant.
Results
ACE2 Deficiency Facilitates Ang II-mediated Aortic
Inflammation
We firstly evaluated the effects of Ang II on aortic expressions
of ACE2 and profilin-1. Western blotting revealed that aortic
profilin-1 expression (Figure 1B) was obviously augmented at 1,
and 2 weeks after Ang II infusion in WT mice compared with
pre-treatment group (n=6; P,0.01, respectively). This change
was consistent with reduced protein of ACE2 (Figure 1A) and
increased levels of plasma Ang II and Ang-(1–7) (Figure 1C) in
WT mice (n=6210; P,0.01, respectively). Chronic Ang II
infusion resulted in a marked increase in plasma Ang II levels
(Figure 1C) without affecting plasma Ang-(1–7) levels in ACE2-
deficient mice (n=10; P,0.01, respectively). We next investigat-
ed Ang II-induced vascular inflammation in ACE2 deficiency
status. TaqMan real-time PCR analysis revealed that lack of
Figure 1. Ang II-mediated aortic expressions of ACE2, profilin-1, and inflammatory cytokines in mice. Representative Western blot
analysis with quantification exhibited aortic expressions of ACE2 (A; 90 kD) and profilin-1 (B; 15 kD) at 0, 1 and 2 weeks after Ang II infusion in WT
mice (n=5). R.E.=relative expression; a-tubulin (55 Kd) was used as an endogenous control.
**P,0.01 compared with pre-treatment group. Plasma
Ang II and Ang-(1–7) levels (C) were measured in WT and ACE2KO mice in response to Ang II (n=10). TaqMan real-time PCR analysis revealed the
mRNA expressions of inflammatory cytokines including MCP-1 (D), IL1b (E), IL6 (F), and TNFa(G) in mice (n=628). A.U.=arbitrary units; MCP-1,
monocyte chemoattractant protein-1; IL1b, interleukin-1b; IL6, interleukin-6;TNFa, tumor necrosis factor-a. 18S rRNA was used as an endogenous
control.
**P,0.01 compared with corresponding vehicle-treated group; #, P,0.05 ##, P,0.01 compared with WT+Ang II group; w, P,0.05
compared with WT+vehicle group.
doi:10.1371/journal.pone.0038502.g001
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expressions of inflammatory cytokines MCP-1 (Figure 1D), IL1b
(Figure 1E) and IL6 (Figure 1F) in ACE2-dificient aortas
(n=628; P,0.01, respectively), without having a differential
effect on the expression of TNF-a (Figure 1G).
ACE2 deficiency enhances Ang II-mediated aortic profilin-1
expression and the Akt/ERK/eNOS activation.
As shown in Figure 2, increased expression of profilin-1 was
exhibited in the aortas of ACE2KO mice associated with
enhanced phospho-ERK1/2 level (n=5; P,0.05, respectively)
without affecting the expressions of phospho-Akt, Akt, phospho-
p70S6K, phospho-eNOS and eNOS. Ang II infusion strikingly
increased the aortic profilin-1 protein (Figure 2A) in both WT
and ACE2 mutant mice (n=5; P,0.01, respectively). Notably, in
response to chronic stimulation by Ang II, there was a greater
increase in profilin-1expression (Figure 2A) in the aortas of
ACE2KO mice along with greater increases in the expression of
phospho-Akt (Ser
473; Figure 2B) and phospho-Akt (Thr
308;
Figure 2C) without affecting Akt (Figures 2B and 2C) as well
as greater increases in phospho-p70S6 kinase (Figure 2D),
phospho-ERK1/2 (Figure 2E), phospho-eNOS and eNOS
(Figure 2F) (n=5; P,0.05, respectively), indicating that loss of
ACE2 resulted in greater increases in aortic profilin-1 expression
and the activation of the Akt/ERK/eNOS signaling pathways.
Figure 2. Ang II-mediated aortic profilin-1 expression and activation of signaling cascades in ACE2KO mice. Representative Western
blot analysis with quantification exhibited aortic protein expression of profilin-1 (A; 15 kD) and phosphorylated levels of Akt at Ser
473 and Thr
308 (B &
C; 60 kD), p70S6K (D; 70 kD), ERK1/2 (E; 44/42 kD) and eNOS (F; 140 kD) in WT and ACE2KO mice in response to Ang II (n=5). R.E.=relative
expression; ERK1/2, extracellular receptor-regulated kinases 1/2; eNOS, endothelial nitric oxide synthase. a-tubulin (55 kD) was used as an
endogenous control.
**P,0.01 compared with corresponding vehicle-treated group; #, P,0.05 compared with WT+Ang II group; w, P,0.05
compared with WT+Vehicle group.
doi:10.1371/journal.pone.0038502.g002
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Peroxynitrite Production
Activation of NADPH oxidase is a central mediator of the
pathological effects of Ang II, contributing to oxidative injury in
the vasculature [8,28,29]. We found that chronic Ang II infusion
significantly enhanced aortic NADPH oxidase activity (Figure 3J)
and the production of superoxide (dihydroethidium fluorescence;
Figures 3B, 3D & 3I) and peroxynitrite (nitrotyrosine staining;
Figures 3F, 3H & 3I) in both WT and ACE2 mutant mice
(n=526; P,0.01, respectively). Furthermore, ACE2-dificient
mice exhibited greater increases in aortic superoxide (Figures 3D
& 3I) and peroxynitrite production (Figures 3H & 3I) associated
with enhanced NADPH oxidase activity (lucigenin-enhanced
chemiluminescence; Figure 3J) (n=526; P,0.05, respectively).
Interestingly, worsen aortic nitrotyrosine formation in ACE2-
dificient mice was further confirmed by Western blot analyses
showing a greater increase in protein level of nitrotyrosine
(Figure 3L) in aortas in response to Ang II (n=526; P,0.05,
respectively), which indicated that loss of ACE2 facilitated Ang II-
mediated peroxynitrite production in the vasculature.
AT1 Blockade Prevents Ang II-mediated Aortic
Inflammation with the Altered ACE2 and Profilin-1
Signaling
Ang II is known to mediate its pathological effects in vascular
system by means of the activation of AT1 receptors [20]. In this
Figure 3. Ang II-mediated aortic superoxide and peroxynitrite generation in ACE2KO mice. Representative dihydroethidium (A–D) and
nitrotyrosine (E–H) fluorescence images, relative fluorescence values (I) and NADPH oxidase activity (J) exhibited aortic superoxide generation and
nitrotyrosine formation and NADPH oxidase activities in WT and ACE2KO mice in response to Ang II. Representative Western blot analysis showed
protein level of nitrotyrosine (K; 60 kD) in aortas of WT and ACE2KO mice infused with Ang II. R.E.=relative expression; KO, knockout; A.U., arbitrary
units; NADPH, nicotinamide adenine dinucleotide phosphate; a-tubulin (55 Kd) was used as an endogenous control. n=526.
**P,0.01 compared
with corresponding vehicle-treated group; #, P,0.05 compared with WT+Ang II group; w, P,0.05 compared with WT+Vehicle group.
doi:10.1371/journal.pone.0038502.g003
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significantly upregulated the protein (Figures 4A) and mRNA
(Figures 4B) expression of ACE2 while strikingly downregulated
the mRNA expressions of inflammatory cytokines MCP-1
(Figure 4C), IL1b (Figure 4D) and IL6 (Figure 4E) without
affecting TNF-a (Figure 4F) in aortas of WT mice (n=528;
P,0.05 or P,0.01, respectively). In addition, the Ang II-induced
aortic profilin-1 expression (Figure 5A) was significantly prevented
by AT1 receptor blockade (n=5; P,0.05, respectively), associated
with normalization of the Ang II-mediated increases in aortic
expressions of phospho-Akt (Ser
473; Figure 5B), phospho-Akt
(Thr
308; Figure 5C), phospho-p70S6 kinase (Figure 5D), phospho-
ERK1/2 (Figure 5E), phospho-eNOS (Figure 5F) and eNOS
(Figure 5F) in WT mice (n=5; P,0.05, respectively). No
significant differences were determined in the Akt expression
among the groups (Figure 5B).
AT1 Blockade Suppresses Ang II-mediated Aortic
Peroxynitrite Production
Blockade of AT1 receptors by irbesartan treatment largely
prevented Ang II-mediated increase in aortic nitrotyrosine staining
(Figures 6F & 6G), superoxide production (Figures 6C & 6G) and
protein level of nitrotyrosine (Figure 6I) in aorta of mice with
suppression of NADPH oxidase activation (Figure 6H) (n=526;
P,0.05, respectively), providing that Ang II mediated activation of
the AT1 receptor is a key pathophysiological event in the aortic
superoxide and peroxynitrite production. Collectively, our data
demonstrated that chronic Ang II infusion resulted in the AT1
receptor-mediated increases in superoxide and peroxynitrite
production in the vasculature via the activation of the NADPH
oxidase and the Akt-ERK-eNOS signaling pathways.
Discussion
It is generally considered that peroxynitrite triggers cellular
responses ranging from subtle modulations of cell signaling to
overwhelming vascular oxidative injury and represents a crucial
pathogenic mechanism of vascular diseases such as hypertension in
experimental animal models and patients [1,6,8]. However, the
molecular changes and signaling mechanisms still remain unclear
in the peroxynitrite generation underlying Ang II-mediated
vascular diseases. Within the vascular system, peroxynitrite is
produced in all layers of the vascular wall by all vascular cell types,
including endothelial, smooth muscle, and adventitial cells. They
are formed by various enzyme systems, including uncoupled
eNOS and NADPH oxidase, and others [1,7,8,26,29]. We have
previously shown that loss of NADPH oxidase reduced Ang II-
mediated superoxide production while enhancement of NADPH
oxidase markedly augmented superoxide production in hearts of
Ang II-infused ACE2 mutant mice [24,28]. In the present study,
we demonstrated that chronic Ang II infusion results in marked
increases in aortic peroxynitrite production in both WT and
Figure 4. Aortic ACE2 expression and inflammation in Ang II-infused mice following irbesartan treatment. Representative Western blot
analysis exhibited aortic protein levels of ACE2 (A) in WT mice (n=5). a-tubulin (55 kD) was used as an endogenous control. TaqMan real-time PCR
analysis showed the mRNA expression of ACE2 (B) and inflammatory cytokines MCP-1 (C), IL1b (D), IL6 (E), and TNF-a(F) in the aortas of WT mice
(n=628). A.U., arbitrary units; Irb, irbesartan; See Figure 1 for other abbreviations.
**P,0.01 compared with WT+vehicle group; #, P,0.05 ##,
P,0.01 compared with WT+Ang II group.
doi:10.1371/journal.pone.0038502.g004
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derived by NADPH oxidase activation. It has become clear that
eNOS normally generates NO from L-arginine by utilizing
NADPH [1,29,30]. Peroxynitrite may oxidize and disrupt the
zinc thiolate center of eNOS by releasing zinc and oxidizing the
thiols. This modification of eNOS (eNOS uncoupling) leads to
diminishment of NO bioactivity and elevation of vascular
superoxide production, which reacts with NO, further generating
ONOO
2 [8]. The present data suggest that the enhancement of
NADPH-derived superoxide may act as a ‘‘kindling radical’’ to
cause eNOS activation and peroxynitrite production in Ang II-
infused mice. Ang II infusion increases, rather than decreases, the
phosphorylation and protein levels of eNOS in both WT and
ACE2-deficient mice. These findings are in line with previous
observations in the rat model of oxidative stress mediated by Ang
II [30] where eNOS expression was significantly upregulated in
aorta tissues. More importantly, our current report exhibited that
AT1 receptor blockade by irbesartan significantly attenuated Ang
II-mediated aortic peroxynitrite production in WT mice, along
with a marked reversal of Ang II-induced activation of NADPH
oxidase and eNOS, confirming a critical contribution of Ang II/
AT1 receptor-mediated activation of NADPH oxidase and eNOS
to the peroxynitrite production.
The pivotal role of ACE2 as a negative regulator of Ang II-
mediated signaling in the vascular system implies that ACE2
deficiency could facilitate the adverse effects of Ang II
[15,16,17,24,28]. In the present study, aortic ACE2 protein is
obviously reduced in WT mice in response to Ang II. This
downregulation of ACE2 by Ang II in WT mice is related to
marked increases in aortic profilin-1 protein. Moreover, absence of
Figure 5. Aortic profilin-1 expression and signaling cascades in Ang II-infused mice following irbesartan treatment. Protein level of
profilin-1 (A; 15 kD) and phosphorylated levels of Akt at Ser
473 and Thr
308 (B & C; 60 kD), p70S6 kinase (D; 70 kD), ERK1/2 (E; 44/42 kD) and eNOS (F;
140 kD) in aortas of WT mice using Western blot analyses. R.E.=relative expression; Irb, irbesartan; See Figure 2 for other abbreviations. a-tubulin
(55 kD) was used as an endogenous control. n=5.
**P,0.01 compared with WT+vehicle group; #, P,0.05 compared with WT+Ang II group.
doi:10.1371/journal.pone.0038502.g005
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ACE2KO mice. In the Ang II-treated ACE2KO mice, loss of
ACE2 triggers a greater increase in aortic profilin-1 expression
linked with higher plasma Ang II levels. Ang II is critically
involved in the activation of inflammatory cytokines, which may in
turn trigger oxidative stress and cardiovascular dysfunction
[2,3,27,31,32]. The key peptidase action of ACE2 is degradation
of Ang II to Ang-(1–7), turning the balance within the RAS
cascade from pro-inflammatory and pro-oxidative actions to anti-
inflammatory and anti-oxidative actions [4,12,28,31]. TaqMan
real-time PCR analysis in this work revealed that lack of ACE2
results in greater increases in Ang II-induced mRNA expression of
inflammatory cytokines MCP-1, IL1b and IL6 in ACE2-dificient
aortas, without having a differential effect on TNF-a expression.
The Ang II-induced aortic inflammation is significantly prevented
by the AT1 receptor blocker irbesartan along with the suppression
of peroxynitrite production and the enhancement of ACE2
expression. This is in agreement with other reports demonstrating
that the enhanced ACE2 is associated with attenuation of Ang II-
induced MCP-1 expression in cultured human monocyte cell line
macrophages [33] and in aortas of the hypertensive rats [17].
Taken together, ACE2 deficiency facilitates Ang II-induced aortic
inflammation and peroxynitrite production while enhanced ACE2
by AT1 receptor blockade is, at least in part, responsible for the
attenuation of aortic inflammation and peroxynitrite generation.
There is growing evidence that profilin-1, a commonly recog-
nized intracellular actin-binding protein, plays a prominent role in
vascular pathology and vascular diseases [13,14,34]. Our current
report for the first time demonstrated that ACE2 deficiency leads
to greater increases in aortic profilin-1 expression in response to
Ang II with the upregulation of eNOS in both phosphorylation
and protein levels. It is not yet known whether this increase of
profilin-1 is of pathophysiological significance in Ang II-mediated
vascular diseases, but it has been revealed that profilin-1 over-
expression leads to vascular inflammation [35] and vascular
remodeling [14,21]. Profilin-1 gene may represent a new thera-
peutic target in the treatment of vascular diseases such as
hypertension [9,10,21]. Interestingly, profilin-1 has been shown
to regulate eNOS phosphorylation and activity under atherogenic
dietary and profilin-1 transgenic or mutant conditions [21,34,35].
Figure 6. Aortic superoxide and peroxynitrite production in Ang II-infused mice following irbesartan treatment. Representative
dihydroethidium (A–C) and nitrotyrosine (D–F) fluorescence images, relative fluorescence values (G) and lucigenin-enhanced chemiluminescence
assay (H) exhibited the aortic superoxide and nitrotyrosine generation and NADPH oxidase activity in WT mice. Protein level of nitrotyrosine (I; 60 kD)
was determined in aortas of WT mice by Western blot analysis. R.E.=relative expression; Irb, irbesartan; A.U., arbitrary units; NADPH, nicotinamide
adenine dinucleotide phosphate; and DPI, diphenyleneiodonium. n=526.
**P,0.01 compared with WT+ vehicle group; #, P,0.05 compared with
WT+Ang II group.
doi:10.1371/journal.pone.0038502.g006
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PLoS ONE | www.plosone.org 8 June 2012 | Volume 7 | Issue 6 | e38502In addition, profilin-1 interacts with signaling molecules including
vasodilator-stimulated phosphoprotein (VASP), a validated marker
for the activity of the eNOS/NO signaling pathway in vascular
tissues [30]. Furthermore, profilin-1 triggers the activation of
PI3K/Akt, which is an important regulator of vascular eNOS
activation and peroxynitrite production through p70S6 kinase and
ERK signaling pathways [2,11,13,21]. In this work, Ang II-
mediated increase in aortic profilin-1 expression is linked with
augmented phosphorylation level of Akt at both regulatory sites,
Ser
473 and Thr
308. In agreement with the pattern of Akt
activation, phosphorylation levels of p70S6 kinase, ERK1/2,
and eNOS are markedly augmented in WT and ACE2 mutant
mice in response to Ang II, when compared with their
corresponding control mice. Long-term blockade of AT1 receptors
by irbesartan significantly augments the mRNA and protein
expression of ACE2. More intriguingly, irbesartan provides
protection against Ang II-mediated aortic peroxynitrite production
via the suppression of profilin-1 expression and the Akt-ERK-
eNOS signaling pathways in the present study. Consistent with our
previous studies [9], these findings suggesting that Ang II-
mediated upregulation of profilin-1 might, in part, contribute to
the vascular peroxynitrite production.
Consequently, our findings demonstrate that ACE2 deficiency
worsens Ang II-induced aortic inflammation and peroxynitrite
production with the augmentation of profilin-1 expression and the
activation of the Akt-ERK-eNOS signaling pathways, suggesting
a critical role of ACE2 in the suppression of Ang II-mediated
vascular injury and potential therapeutic approaches by enhancing
ACE2actionforpatientswithvasculardiseases.NewrolesforACE2
may yet remain to be discovered and elucidated in the vascular
biology. As highlighted in this work, further studies are required to
betterdefinethechangesinvascularprofilin-1levelsandtherelative
contribution and precise mechanism of profilin-1 in the inflamma-
tion and peroxynitrite production in the vasculature.
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